gip glp 1 glucagon agonists New strategies for the treatment of obesity and metabolic dysfunctions Science Behind GLP 1 GIP

This review examines the biological mechanisms underlying GLP-1 RA therapy in MASLD/MASH, analyzes the mechanistic distinctions between mono-, dual-, and triple agonists, and synthesizes current clinical evidence supporting their utilization in individuals with this condition.

Insurers find themselves in the position of needing to say "yes" or "no" to GLP-1 drugs as more people seek them for weight loss

Read how the new Wegovy pill compares to shots like Ozempic to learn which form might be best for you.

Retatrutide reported up to 28.7% average weight loss and pain reduction of up to 75.8% on the WOMAC scale in adults with obesity and knee osteoarthritis [9]

While fasting GLP-1 remained largely unchanged, postprandial concentrations rose markedly at 6 months (total AUC increase in RYGB: ~330%, OAGB: ~259%